IMV Inc. to Announce 2018 Fourth Quarter & Fiscal Year-End Results & Host Investor Conference Call & Webcast on March 22, 2019
March 08 2019 - 7:05AM
Business Wire
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a
clinical stage immunotherapy company, announced today that it will
hold a conference call and webcast on Friday, March 22, 2019 at
8:00 a.m. ET to discuss the company’s 2018 fourth quarter and
fiscal year-end financial and operational results.
Financial analysts are invited to join the conference call by
dialing (844) 461-9932 (U.S. and Canada) or (636) 812-6632
(international) using the conference ID: 9647179.
Other interested parties will be able to access the live audio
webcast at this link:
https://ir.imv-inc.com/events-and-presentations. The webcast will
be recorded and will then be available on the IMV website for 30
days following the call.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks
and uncertainties include, but are not limited to, our ability to
access capital, the successful and timely completion of clinical
trials, the receipt of all regulatory approvals and other risks
detailed from time to time in our ongoing quarterly filings and
annual information form. Investors are cautioned not to rely on
these forward-looking statements and are encouraged to read IMV’s
continuous disclosure documents, including its current annual
information form, as well as its audited annual consolidated
financial statements which are available on SEDAR
at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190308005046/en/
MEDIA:Andrea Cohen, Sam Brown Inc.O: (917)
209-7163 E: andreacohen@sambrown.comINVESTOR
RELATIONSMarc Jasmin, IMV Senior Director, Investor
Relations and CommunicationsO: (902) 492-1819M: (514) 917-9481
E: mjasmin@imv-inc.com
Patti Bank, Managing Director, Westwicke PartnersO: (415)
513-1284M: (415) 515-4572 E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024